There are 2949 resources available
1410P - Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
Presenter: Jiaxin Niu
Session: E-Poster Display
Resources:
Abstract
1411TiP - GFPC 06-2018: A multicenter non-randomized phase II study evaluating platinum-pemetrexed-atezolizumab (+/-bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after targeted therapies
Presenter: Olivier Bylicki
Session: E-Poster Display
Resources:
Abstract
1412TiP - Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins)
Presenter: Pasi Jänne
Session: E-Poster Display
Resources:
Abstract
1413TiP - LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC)
Presenter: Herbert Loong
Session: E-Poster Display
Resources:
Abstract
1414TiP - Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort
Presenter: D. Ross Camidge
Session: E-Poster Display
Resources:
Abstract
1415TiP - INSIGHT 2: Tepotinib + osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
Presenter: Egbert Smit
Session: E-Poster Display
Resources:
Abstract
1416TiP - CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
Presenter: Martin Reck
Session: E-Poster Display
Resources:
Abstract
1417TiP - Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial
Presenter: Matthias Guckenberger
Session: E-Poster Display
Resources:
Abstract
1418TiP - Randomized, placebo-controlled phase III study of 1L pembrolizumab (Pembro) plus carboplatin/taxane followed by pembro with or without maintenance olaparib in patients (Pts) with metastatic squamous non-small cell lung cancer (sqNSCLC): KEYLYNK-008
Presenter: Jhanelle E Gray
Session: E-Poster Display
Resources:
Abstract
1419TiP - ARC-7: A phase II study to evaluate the safety and efficacy of zimberelimab alone, AB154 in combination with zimberelimab, and AB154 in combination with zimberelimab and AB928 in front-line, PD-L1 expressing, non-small cell lung cancer (NSCLC)
Presenter: Arvind Chaudhry
Session: E-Poster Display
Resources:
Abstract